A single Phase 3 trial failure costs between $800 million and $1.4 billion, including lost time-to-market. The leading cause is patient recruitment. HEKMA eliminates that risk before your trial starts.
30 to 50% of all clinical trial delays are caused by patient recruitment failures. A one-month Phase 3 delay costs $600K to $8M in direct costs alone. (McKinsey, 2024 / Tufts CSDD)
$40K–$80K
average cost per enrolled patient, traditional recruitment
20%
over-recruitment buffer pharma builds in to compensate for dropout
$1.4B
average Phase 3 failure cost, mostly from enrollment failure
The Cost of Getting Recruitment Wrong
0%
Delays from recruitment
of all clinical trial delays
0%
Screen failure rate
industry average
$0M
Monthly delay cost
Phase 3 direct costs
“The leading cause of Phase 3 failure is not the science. It is patient recruitment. Most sponsors commit to timelines before they know whether the patients actually exist in their target geography.”
McKinsey Global Institute, Clinical Operations Report 2024
Traditional recruitment tools: site-based outreach, investigator networks, social media ads, were designed when patients lived near trial sites and knew trials existed. Neither assumption holds today. The result is a systemic enrollment crisis that costs sponsors billions per year.
Sources: Roots Analysis 2025, Tufts Center for the Study of Drug Development, McKinsey 2024
$1.4B
average Phase 3 failure cost
majority attributed to enrollment failure
Four steps from protocol submission to a fully enrolled, CTMS-managed trial.
Upload your trial protocol or we pull it from ClinicalTrials.gov. Our AI parses all inclusion and exclusion criteria automatically. No manual data entry, no waiting for a kickoff call.
Protocol loaded in under 1 hour.
HEKMA runs your criteria against our hospital EHR network, H360 database, and 50+ PAG communities. You receive a tiered confidence report with exact patient counts, geography, and timeline.
Population report in 5 business days.
We run targeted campaigns across 5 simultaneous channels: EHR matching, H360 app, PAG communities, digital media, and hospital referrals. Every candidate is pre-screened against your I/E criteria.
Pre-screened patients delivered to your sites.
HEKMA CTMS handles protocol distribution, adverse event tracking, blinded study management, 21 CFR Part 11 audit trails, and multi-site coordination. Deployed in days, not months.
Full compliance, live in days.
Protocol Upload
< 1 hour
Population Report
5 business days
Recruitment Launch
Days later
First Patient
Weeks, not months
Give us your protocol. We will show you how many eligible patients exist, where they are, and how fast you can enroll, before you commit to anything.
Enterprise platforms built for Pfizer are the wrong fit for most sponsors. Here is what that costs you.
Broad site estimates, educated guesses on patient population numbers
Real EHR patient counts matched against your specific I/E criteria
Data-backed timeline, sponsor confidence
$40K+ per recruited patient with 60% average screen failure rate
AI pre-screening reduces screen failure to under 20%
Lower cost per enrolled patient
Veeva or Medidata at $250K minimum, 6 to 12 months to deploy
CTMS live in days, per-trial pricing, no annual platform fees
Full compliance at a fraction of the cost
Site-based recruitment, limited geographic and demographic reach
EHR, H360, PAG, digital, and hospital referrals: 5 simultaneous channels
Faster enrollment, lower dropout risk
One platform. No four vendor contracts. No integration tax.
We find your patients. EHR matching across our hospital network, AI matching via H360, targeted digital campaigns. We identify, screen, and deliver pre-qualified candidates for your specific trial, indication, and geography.
Once enrolled, we manage your trial. Protocol management, adverse event tracking, blinded study management, 21 CFR Part 11 compliance, and multi-site coordination, all deployed in weeks, not months.
Veeva and Medidata were built for companies running 50+ trials. HEKMA is built for teams running their first three. Per-trial pricing, deploy in days, one platform instead of four vendor contracts.
An AI-powered matching marketplace connecting clinical sponsors with the highest density of eligible patient populations globally.
The enterprise platform for trial execution, managing every workflow from site onboarding to regulatory submission with clinical rigor.
Leverage Hekma's deep data lake and AI models to identify eligible patients months before your competitors. We don't just find sites; we find the specific patients within those sites that meet every inclusion and exclusion criteria.
Patient Intelligence
Streamline the entire lifecycle of your trial with a CTMS that actually talks to your other systems. From digital consent to monitoring reports, we automate the manual overhead that slows down progress.
Trial Management
Five indication families with dense EHR coverage, PAG partnerships, and AI-trained matching models.
Heart failure, AFib, hypertension, cardiometabolic conditions. Large patient pools and high trial volume across our hospital EHR network.
Solid tumors, hematologic malignancies, immuno-oncology, precision oncology. Deepest EHR network coverage.
Alzheimer's, Parkinson's, multiple sclerosis, rare neurological disorders. Complex I/E criteria where AI matching specialises.
Ultra-specific patient populations, PAG partnerships, H360 rare disease registry. Where traditional outreach fails, HEKMA delivers.
Class II/III device trials, SaMD validation, post-market surveillance (522 studies, PMCF). Device-specific EHR matching with CPT codes and surgical notes.
Enterprise incumbents like Veeva and Medidata were built for the overhead of Top 10 Pharma. Hekma provides the same enterprise-grade power with a fraction of the implementation time and cost.
Be up and running in weeks, not 6+ months of consulting.
Direct API-first architecture for your internal data scientists.
Scale as you grow. No hidden seat taxes that penalize your team.
21 CFR Part 11 and GCP baked into every single click.
Hekma vs. Enterprise Legacy
Time to deploy
6-12 months
Days
Minimum contract
$250K+
Per-trial
Screen failure rate
~60%
<20%
Integrations needed
4+ vendors
1 platform
Compliance and Regulatory Standards
Give us your protocol. We will show you how many eligible patients exist in our network, where they are, and how fast you can enroll, before you commit to a timeline.